Glycoxidation and lipoxidation in atherogenesis

Free Radical Biology and Medicine

Volumn 28, Issue 12, 2000, Pages 1708-1716

  Baynes, John W ^a,b   Thorpe, Suzanne R ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation end products (AGEs); Advanced lipoxidation end products (ALEs); Aging; Carbonyl stress; Free radicals; Glycoxidation; Lipid peroxidation; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBONYL DERIVATIVE; FREE RADICAL; LIPID;

AGING; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CHEMICAL MODIFICATION; DIABETES MELLITUS; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 0034659178     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(00)00228-8     Document Type: Article

References (73)

1. Griffin B.A. Lipoprotein atherogenicity an overview of current mechanisms . Prog. Nutr. Soc. 58:1999;163-169.
2. Pentikainen M.O., Lehtonen E.M., Kovanen P.T. Aggregation and fusion of modified low density lipoprotein. J. Lipid Res. 37:1996;2638-2649.
3. Watson A.D., Leitinger N., Navab M., Faull K.F., Horkko S., Witztum J.L., Palinski W., Schwenke D., Salomon R.G., Sha W., Subbanagounder G., Fogelman A. M; Berliner, J. A. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272:1997;13597-13607.
4. Liu T., Stern A., Roberts L.J., Morrow J.D. The isoprostanes novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid . J. Biomed. Sci. 6:1999;226-235.
5. Rosenfeld M.E., Palinski W., Yla-Herttuala S., Butler S., Witztum J.L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:1990;336-349.
6. Requena, J. R.; Fu, M-X.; Ahmed, M. U.; Jenkins, A. J.; Lyons, T. J.; Thorpe, S. R. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol. Dial. Transplant. 11(Suppl. 5):48-53; 1996.
7. 2-protein adducts in human plasma and vasculature. Chem. Res. Toxicol. 10:1997;536-545.
8. Thorpe S.R., Baynes J.W. The role of oxidative stress in diabetic complications a new perspective on an old paradigm . Diabetes. 48:1999;1-9.
9. Golubev A.G. The other side of metabolism. Biokhimiia. 61:1996;2018-2039.
10. Sakata N., Imanaga Y., Meng J., Tachikawa Y., Takebayashi S., Nagai R., Horiuchi S., Itabe H., Takano T. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis. 141:1998;61-75.
11. Miyata T., Ishikawa S., Asahi K., Inagi R., Suzuki D., Horie K., Tatsumi K., Kurokawa K. 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery role of glycoxidation and lipoxidation reactions in vascular damage . FEBS Lett. 445:1999;202-206.
12. Valera A., Pujol A., Pelegrin M., Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA. 91:1994;9151-9154.
13. Esterbauer H., Gebicki J., Puhl H., Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med. 13:1992;341-390.
14. Spiteller G. Linoleic acid peroxidation - the dominant lipid peroxidation process in low density lipoprotein - and its relationship to chronic diseases. Chem. Phys. Lipids. 95:1998;105-162.
15. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128.
16. Sayre L.M., Sha W., Xu G., Kaur K., Nadkarni D., Subbagagounder G., Salomon R.G. Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Chem. Res. Toxicol. 9:1996;1194-1201.
17. Tsai L., Szweda P.A., Vinogradova O., Szweda L.I. Structural characterization and immunochemical detection of a fluorophore derived from 4-hydroxy-2-nonenal and lysine. Proc. Natl. Acad. Sci. USA. 95:1998;7975-7980.
18. Uchida K., Kanematsu M., Sakai K., Matsuda T., Hattori N., Mizuno Y., Suzuki D., Miyata T., Noguchi N., Nike E., Osawa T. Protein-bound acrolein potential markers for oxidative stress . Proc. Natl. Acad. Sci. USA. 95:1998;4882-4887.
19. ε-(hexanoyl)lysine in protein exposed to lipid hydroperoxide. A plausible marker for lipid hydroperoxide-derived protein modification. J. Biol. Chem. 274:1999;20406-20410.
20. Terman A., Brunk U.T. Lipofuscin mechanisms of formation and increase with age . AMPIS. 106:1998;B265-B276.
21. Ledl F., Schleicher E. New aspects of the Maillard reaction in foods and in the human body. Angew. Chem. Int. Ed. Engl. 29:1990;565-706.
22. Njoroge F.G., Monnier V.M. The chemistry of the Maillard reaction under physiological conditions a review . Prog. Clin. Biol. Res. 304:1989;85-107.
23. Thornalley P.J. Pharmacology of methylglyoxal. Gen. Pharmacol. 27:1996;565-573.
24. Lal S., Randall W.C., Taylor W.H., Kappler F., Walker M., Brown T.R., Szwergold B.S. Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts. Metabolism. 46:1997;1333-1338.
25. Hayase F., Nagaraj R.H., Miyata S., Njoroge F.G., Monnier V.M. Aging of proteins immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo . J. Biol. Chem. 264:1989;3758-3764.
26. α-acetyl-lysine, and bovine serum albumin. J. Biol. Chem. 269:1994;32299-32305.
27. Niwa, T.; Katsuzaki, T.; Miyazaki, S.; Miyazaki, T.; Ishizaki, Y.; Hayase, F.; Tatemichi, N.; Takei, Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J. Clin. Invest. 99:1272-1280.
28. Shipanova I.N., Glomb M.A., Nagaraj R.H. Protein modification by methylglyoxal chemical nature and synthetic mechanism of a major fluorescent adduct . Arch. Biochem. Biophys. 344:1997;29-36.
29. Oya T., Hattori N., Mizuno Y., Miyata S., Maeda S., Osawa T., Uchida K. Methylglyoxal modification of protein chemical and immunochemical characterization of methylglyoxal-arginine adducts . J. Biol. Chem. 274:1999;18492-18502.
30. Sell D. R; Monnier, V. M. Structure elucidation of a senescence cross-link from human extracellular matrix implication of pentoses in the aging process . J. Biol. Chem. 264:1989;21597-21602.
31. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo . J. Biol. Chem. 266:1991;11654-11660.
32. Obayashi H., Nakano K., Shigeta H., Yamaguchi M., Yoshimori K., Fukui M., Fujii M., Kitagawa Y., Nakamura N., Nakamura K., Nakazawa Y., Ienaga K., Ohta M., Nishimura M., Fukui I., Kondo M. Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. Biochem. Biophys. Res. Commun. 226:1996;37-41.
33. Nakamura K., Nakazawa Y., Ienaga K. Acid-stable fluorescent advanced glycation end products vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose . Biochem. Biophys. Res. Commun. 232:1997;227-230.
34. Tessier F., Obrenovich M., Monnier V.M. Structure and mechanism of formation of human lens fluorophore LM-1. Relationship to vesperlysine A and the advanced Maillard reaction in aging, diabetes, and cataractogenesis. J. Biol. Chem. 274:1999;20796-20804.
35. Dyer D.G., Dunn J.A., Thorpe S.R., Bailie K.E., Lyons T.J., McCance D.R., Baynes J.W. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 91:1993;2463-2469.
36. ε-(carboxyethyl)lysine, a product of chemical modification of protein by methylglyoxal, increases with age in human lens proteins. Biochem. J. 324:1997;565-570.
37. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271:1996;9982-9986.
38. Brinkmann Frye E., Degenhardt T.P., Thorpe S.R., Baynes J.W. Role of the Maillard reaction in aging of tissue proteins age-dependent increase in imidazolium crosslinks in human lens protein . J. Biol. Chem. 273:1998;18714-18719.
39. Chellan P., Nagaraj R.H. Protein crosslinking by the Maillard reaction; dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch. Biochem. Biophys. 368:1999;98-104.
40. Degenhardt T.P., Thorpe S.R., Baynes J.W. Chemical modification of proteins by methylglyoxal. Cell. Mol. Biol. 44:1998;1139-1145.
41. Meng J., Sakata N., Takebayashi S., Asano T., Futata T., Nagai R., Ikeda K., Horiuchi S., Myint T., Taniguchi N. Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis. 136:1998;355-365.
42. ε-(carboxymethyl)lysine on proteins a mechanism for producing advanced glycation end products at sites of inflammation . J. Clin. Invest. 104:1999;103-113.
43. Leeuwenburgh C., Rasmussen J.E., Hsu F.F., Mueller D.M., Pennathur S., Heinecke J.W. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J. Biol. Chem. 272:1997;3520-3526.
44. Heinecke J.W. Mass spectrometric quantification of amino acid oxidation product in proteins insights into pathways that promote LDL oxidation in the human artery wall . FASEB J. 13:1999;1113-1120.
45. Martens J.S., Lougheed M., Gómez-Muñoz A., Steinbrecher U.P. A modification of apoliprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein. J. Biol. Chem. 274:1999;10903-10910.
46. Hardwick S.J., Carpenter K.L., Allen E.A., Mitchinson M.J. Glutathione (GSH) and the toxicity of oxidized low density lipoprotein to human monocyte-macrophages. Free Radic. Res. 30:1999;11-19.
47. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. Activation of receptor for advanced glycation end products a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis . Circ. Res. 19:1999;489-497.
48. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 37:1998;586-600.
49. Saxena A.K., Saxena P., Wu X., Obrenovich M., Weiss M.F., Monnier V.M. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding relevance to diseases of glycoxidative stress . Biochem. Biophys. Res. Commun. 260:1999;332-338.
50. Lee C., Yim M.B., Chock P.B., Yim H.S., Kang S.O. Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation. J. Biol. Chem. 273:1998;25272-25278.
51. Lyons T.J., Jenkins A.J. Lipoprotein glycation and its metabolic consequences. Curr. Opin. Lipidol. 8:1997;174-180.
52. Lyons T.J., Jenkins A.J. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes a carbonyl stress hypothesis . Diabetes Metab. Rev. 5:1997;365-391.
53. Vlassara H., Li Y.M., Imani F., Wojciechowicz D., Yang Z., Liu F.T., Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE) a new member of the AGE-receptor family . Mol. Med. 1:1995;634-636.
54. Sano H., Nagai R., Matsumoto K., Horiuchi S. Receptors for proteins modified by advanced glycation endproducts (AGE) - their functional role in atherosclerosis. Mech. Ageing. Dev. 15:1999;333-346.
55. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J. Jr, Chow W.S., Stern D., Schmidt A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4:1998;1025-1031.
56. McCall M.R., Frei B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic. Biol. Med. 26:1999;1034-1053.
57. Suarna C., Dean R.T., May J., Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler. Thromb. Vasc. Biol. 15:1995;1616-1624.
58. Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 232:1986;1629-1632.
59. Baynes J.W. Reactive oxygen in the aetiology and complications of diabetes. Ioannides C. Drugs, diet and disease, vol. 2 mechanistic approaches to diabetes . 1995;203-240 Pergamon Press, London.
60. Bucala R., Vlassara H. Advanced glycosylation endproducts in diabetic renal disease clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition . Blood Purif. 13:1995;160-170.
61. Nakamura S., Makita Z., Ishikawa S., Yasumura K., Fujii W., Yanagisawa K., Kawata T., Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes. 46:1997;895-899.
62. Soulis T., Sastra S., Thallas V., Mortensen S.B., Wilken M., Clausen J.T., Bjerrum O.J., Petersen H., Lau J., Jerums G., Boel E., Cooper M.E. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia. 42:1999;472-479.
63. Shoda H., Miyata S., Liu B.F., Yamada H., Ohara T., Suzuki K., Oimomi M., Kasuga M. Inhibitor effects of tenilsetam on the Maillard reaction. Endocrinology. 138:1997;1886-1892.
64. Booth A.A., Khalifah R.G., Todd P., Hudson B.G. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J. Biol. Chem. 272:1997;5430-5437.
65. Khalifah R.G., Baynes J.W., Hudson B.G. Amadorins novel post-Amadori inhibitors of advanced glycation reactions . Biochem. Biophys. Res. Commun. 257:1999;251-258.
66. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA. 91:1994;9441-9445.
67. Panagiotopoulos S., O'Brien R.C., Bucala R., Cooper M.E., Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis. 136:1998;125-131.
68. Corman B., Duriez M., Poitevin P., Heudes D., Bruneval P., Tedgui A., Levy B.I. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc. Natl. Acad. Sci. USA. 95:1998;1301-1306.
69. Philis-Tsimikas A., Parthasarathy S., Picard S., Palinski W., Witztum J.L. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Atheroscler. Thromb. Vasc. Biol. 15:1995;367-376.
70. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 83:1999;25F-29F.
71. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diab. Care. 18:1995;258-268.
72. Requena J.R., Fu M.-X., Ahmed M.U., Jenkins A.J., Lyons T.J., Baynes J.W., Thorpe S.R. Quantitation of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J. 322:1997;317-325.
73. Wells-Knecht M.C., Lyons T.J., McCance D.R., Thorpe S.R., Baynes J.W. Age-dependent accumulation of ortho-tyrosine and methionine sulfoxide in human skin collagen is not increased in diabetes evidence against a generalized increase in oxidative stress in diabetes . J. Clin. Invest. 100:1997;839-846.